Reported Saturday, Genentech's Phase III STARGLO Study Shows Columvi Increases Survival For Patients With Relapsed Or Refractory Diffuse Large B-cell Lymphoma
Reported Saturday, Genentech's Phase III STARGLO Study Shows Columvi Increases Survival For Patients With Relapsed Or Refractory Diffuse Large B-cell Lymphoma
據週六報道，Roche旗下的吉利德（Genentech）公司的第3期STARGLO研究表明Columvi可提高復發或難治性瀰漫性大B細胞淋巴瘤患者的生存率。
– The study met its primary endpoint of overall survival with a 41% reduction in the risk of death in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with Columvi plus chemotherapy –
使用Columvi聯合化療治療複發性或難治性瀰漫性B細胞淋巴瘤的患者，可以將死亡風險降低41%，達到主要研究終點。
– This Columvi combination could provide a much-needed off-the-shelf treatment option for people with transplant-ineligible R/R DLBCL –
這種Columvi聯合方案可以爲不能接受移植的複發性或難治性瀰漫性B細胞淋巴瘤患者提供所需的現成治療選擇。
– Data were featured in the congress Press Briefing and presented today in the Plenary Abstracts Session at EHA 2024 as a late-breaking oral presentation –
數據被選爲大會新聞發佈會的特色板塊，並以遲到的口頭髮言方式在EHA 2024的全會摘要會議上展示。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。